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CLINICAL VIGNETTES
The hyperpolarization-activated cyclic nucleotide-gated (HCN) cation (Na+/K+) currents (If/Ih) are generated by 4 members of the channel family (HCN1–4).1 These currents contribute to the pacemaker function2 in heart and brain.3 The 
HCN4 current is known to play a crucial role in the automaticity of the sinus node 
through the generation of a slow diastolic depolarization during the phase 4 of the 
cardiac action potential.4 Thus, it is a crucial channel for appropriate pacemaker activity 
and conduction system function because it facilitates rapid repolarization. Interestingly, 
HCN4 has been shown to be expressed in essentially the entire heart tissue.5 Mutations 
in HCN4 have been associated mainly with sick sinus syndrome phenotype6; however, 
in recent years, a broad spectrum of phenotypes has been reported, including sinus 
bradycardia,7 inappropriate sinus tachycardia,8 early-onset atrial fibrillation,9,10 atrio-
ventricular block,11,12 idiopathic ventricular tachycardia,13 left ventricular noncompac-
tion (LVNC),14–17 dilation of the aorta, and mood and anxiety disorders.19 In the present 
study, we report a case with sick sinus syndrome, LVNC, mood and anxiety disorders, 
and ventricular fibrillation (VF) hosting 2 novel HCN4-pore mutations.
CASE REPORT
The index patient was a 36-year-old man, who presented initially with mood and 
anxiety disorders characterized by important depressive episodes. Previous clini-
cal records revealed a slightly impaired left ventricular function, paroxysmal atrial 
fibrillation, frequent premature ventricular complexes, and nonsustained tachycar-
dia originating from the right ventricle. Therapy with β-blocker was initiated but 
discontinued shortly because of profound sinus bradycardia, which did not resume 
after washout. A cardiac magnetic resonance imaging excluded a right ventricu-
lar cardiomyopathy. The left ventricle showed an uncommon hypertrabeculation; 
however, the criteria for an LVNC were not fulfilled at that time.
Eight years later, the patient was hospitalized because of heart failure and rapid 
conducted atrial fibrillation. At this time, he exhibited a severely depressed left 
ventricular function with left ventricular end-diastolic diameter of 62 mm, reduced 
right ventricular function (tricuspid annular plane systolic excursion of 8 mm) and 
biventricular apical hypertrabeculation more pronounced in the left side. With a 
β-blocker and amiodarone, spontaneous conversion to sinus rhythm occurred, but 
marked sinus bradycardia was noted, despite reduction of β-blocker and amio-
darone doses (Figure 1A). While hospitalized, he presented frequent premature 
ventricular complexes and VF with the need of resuscitation (Figure 1B).
Reversible causes for VF were excluded, the resting electrocardiogram exhibited 
sinus bradycardia and left anterior fascicular block (Figure 1C). The echocardiogra-
phy after recompensation of heart failure was diagnostic for LVNC20,21 and showed 
an improved biventricular function (Figure 1D). A dual-chamber internal cardiovert-
er defibrillator was implanted, and a dual chamber with rate response stimulation at 
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90 beats per minute with a long atrio-ventricular delay 
to avoid ventricular stimulation successfully prevented 
further ventricular arrhythmias. After 2 months, the 
stimulation rate was reduced to 70 beats per minute.
The patient’s arrhythmic and LVNC phenotype at 
relatively young age raised a suspicion for a possible 
underlying inherited arrhythmogenic condition; there-
fore, genetic testing and familial evaluation were rec-
ommended. Because of patient’s limited contact with all 
first-degree relatives, cardiac evaluation was only pos-
sible in 1 brother who was asymptomatic. The mother 
had a pacemaker implanted at 47 years of age and died 
15 years later because of coronary heart disease; no tis-
sue was available. The father died at 86 years of age, 
from an unknown cause.
METHODS
Subjects
The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of reproduc-
ing the results or replicating the procedure because of patient 
confidentiality policy.
This study was conducted in full agreement with the 
principles of the Declaration of Helsinki and laws and regula-
tions of Switzerland. All DNA donors available for this study 
signed an informed consent form approved by the local ethi-
cal committee.
Molecular Genetic Analysis
DNA was extracted from peripheral blood using standard pro-
cedures. Candidate gene sequencing was performed using 
the TruSight One Sequencing Panel (Illumina, San Diego, CA), 
containing 4813 genes associated with known clinical pheno-
types. One hundred ninety-three genes previously associated 
with cardiac diseases were analyzed. Read alignment and local 
realignment of indels were performed using CLC Workbench 
v7.5.1 (Qiagen, Redwood City, CA). We used a number of 
different databases (HGMD Professional; Qiagen, Redwood 
City, CA) and published original literature to identify known 
disease-causing mutations in the datasets from the patients. 
Novel, putative disease-associated sequence variants were 
distinguished from polymorphisms using the following filter-
ing criteria: a change in the protein’s primary structure, spe-
cies conservation of the underlying amino acid, and an allele 
frequency <1% based on the 1000 Genome Project database. 
For detailed sequence analysis and interpretation of sequence 
variations, we used the following bioinformatic algorithms and 
Figure 1. Electrocardiogram and echocardiographic characteristics of the proband.  
A, Persistent sinus bradycardia after conversion from atrial fibrillation, despite low dose of β-blocker. Top to Bottom, simultane-
ous recording of ECG lead II, oxygen saturation wave, ECG lead V1, and respiratory wave. B, Premature ventricular complexes 
triggering nonsustained ventricular tachycardia, followed by ventricular fibrillation with the need of resuscitation and external 
defibrillation (not shown). Top to Bottom, simultaneous recording of ECG lead II, PLETH (plethysmograph, oxygen saturation 
wave, disconected), ECG lead V1, and ECG lead aVR. C, 12-lead ECG at rest, showing sinus bradycardia, left anterior fascicular 
block, and isodifasic T waves from V2 through V6. D, Four-chamber view echocardiogram after heart failure recompensation 
consistent with the diagnosis of left ventricular noncompaction cardiomyopathy (1. thickened myocardium with a noncom-
pacted inner layer and compacted outer layer; 2. thickness ratio of noncompacted-to-compacted myocardium, >2; 3. typical 
predominant localization apical, midlateral, and midinferior21; and 4. thickness of the compacted myocardium, <8.1 mm).20 ECG 
indicates electrocardiogram.
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databases: Polyphen2,22 the Sorting Tolerant From Intolerant‘ 
(SIFT) algorithm,23 Mutation Taster,24 Human Gene Mutation 
Database (HGMD Biobase; Qiagen, Redwood City, CA), 1000 
Genomes,25 and the Exome Aggregation Consortium browser.26 
For titin protein, encoded by TTN, we considered as putative 
mutations only radical mutations (ie, nonsense, frameshift, and 
splice-site mutations). Final interpretation of variants was per-
formed following the guidelines established by the American 
College of Medical Genetics and Genomics.27
Functional Assay
Human embryonic kidney (HEK)-293 cells were cultured in 
Dulbecco modified Eagle medium (Euroclone, Milan, and 
Italy) supplemented with 10% fetal bovine serum (Euroclone, 
Milan, and Italy), 1% Pen Strep (100 U/mL of penicillin and 
100 µg/mL of streptomycin), and stored in a 37°C humidi-
fied incubator with 5% CO2. HEK-293 cells were transiently 
transfected with WT (wild type) or mutant human HCN4 
cDNA (codon-optimized synthesis using the Gene Art service 
by Thermo Fisher Scientific, Waltham, MA) using Turbofect 
transfection reagent (Thermo Fisher, Waltham, MA) accord-
ing to the manufacturer’s recommended protocol. For each 
35-mm Petri dish, 1 µg or 0.5 µg of the HCN4-containing 
vector (pcDNA3.1) and 0.3 µg of green fluorescent protein 
(GFP)-containing plasmid (pmaxGFP; AmaxaBiosystems, 
Gaithersburg, MD) were used. In heteromeric studies, the 
amount of each HCN4 plasmid was 0.5 µg per Petri dish. In 
the control cell, 1.3 µg of GFP-containing plasmid was used 
for the transfection. Thirty to 72 hours after the transfection, 
the cells were dispersed by trypsin treatment. Green fluo-
rescent cells were selected for patch-clamp experiments at 
room temperature (≈25°C). Currents were recorded in whole 
cell configuration with a Dagan 3900A (Degan, Minneapolis, 
MN); data were digitized with an Axon Digidata 1322 A/D 
(Axon Instruments, CA) converter and analyzed off-line with 
Axon pClamp9. Patch pipettes were fabricated from 1.5 
mm outer diameter borosilicate glass capillaries with a P-97 
Flaming/Brown Micropipette Puller (Sutter, Novato, CA) and 
had resistances of 3 to 5 mol/LΩ. The pipettes were filled 
with a solution containing 10 mmol/L NaCl, 130 mmol/L KCl, 
1 mmol/L EGTA, 0.5 mmol/L MgCl2, 2 mmol/L ATP (mg salt), 
and 5 mmol/L HEPES–KOH buffer (pH 7.4). The extracellular 
bath solution contained 110 mmol/L NaCl, 30 mmol/L KCl, 
1.8 mmol/L CaCl2, 0.5 mmol/L MgCl2, and 5 mmol/L HEPES–
KOH buffer (pH 7.4).
For channel activation, hyperpolarizing steps (ranging 
from −160 to −25 mV) of variable duration, sufficient to reach 
steady-state activation at all voltages, were applied from a 
holding potential of −40 mV, and current tails were measured 
on return to a fixed voltage (−40 mV). Only cells in which a 
1 GΩ seal or better was achieved were kept for analysis. No 
leak subtraction was used.
To analyze current density, the steady-state current ampli-
tude was measured at the end of each test potential and 
normalized to cell capacitance. Mean activation curves were 
obtained by fitting maximal tail current amplitude, plotted 
against the voltage step applied, with the Boltzmann equa-
tion It=It(max)/(1+exp(V−V1/2)/k where It is the current ampli-
tude of the tail current recorded for a given prepulse and 
It(max) is the maximum current amplitude of the tail current, 
V is the voltage of the prepulse, V1/2 is the half-activation volt-
age, and k is the slope factor in mV using Originpro software 
(Originlab, Northampton, MA). Activation time constants 
were obtained by fitting with a single exponential function, 
I=I0exp (−t/τ), to current activation time courses during the 
hyperpolarizing reported steps. All comparisons were made 
using unpaired Student t tests with Origin software. All data 
are presented as mean±SEM.
RESULTS
Two novel mutations in the HCN4 gene were found 
in the proband: c.1454C>A p.(Ala485Glu) and 
c.1435A>G p.(Ile479Val). Both variants were present 
in the same Next Generation Sequencing reads sug-
gesting that they were in cis c.(1454C>A; 1435A>G). 
They both localized to the pore region of the HCN4 
channel and were predicted to be pathogenic by SIFT, 
Polyphen2, Mutation Taster, and were absent in HGMD, 
1000 Genomes, and Exome Aggregation Consortium 
Browser encompassing >60 000 sequenced exomes. 
The patient’s brother did not carry any of the 2 HCN4 
mutations. No tissue was available from the parents for 
genetic examination.
Transfected HEK-293 cells transiently express-
ing the WT and the mutant channels were subjected 
to electrophysiological measurements, example cur-
rents were obtained from cells transfected with 1 µg 
of HCN4 plasmid, whereas cells transfected with only 
GFP plasmid served as a control. (Figure 2A and 2B). 
WT channels produced the typical time- and voltage-
dependent inward currents that result in the current/
voltage relationship and activation curve (Figure 2C and 
2D). By fitting the Boltzmann equation to the activa-
tion curve (Figure  2D), we obtained a half-activation 
value of −103.1±0.2 mV and a slope factor k=11±0.2 
mV. These values are consistent with published data on 
HCN428 functionally expressed in HEK-293 cells. Nota-
bly, transfection of 1 µg of the single mutants (I479V 
and A485E), as well as of the double mutant (I479V/
A485E), did not generate any measurable HCN4-like 
current (Figure 2A). The small current of these cells is 
indistinguishable from that of the control cells, trans-
fected with GFP only (Figure  2A and current/voltage 
relationship in Figure 2C).
When the double mutant was cotransfected with 
the WT channel (0.5 µg each plasmid), cells exhibited 
typical HCN4-like currents (Figure 2B). A detailed analy-
sis showed that the voltage dependence (Figure 2D) of 
these currents and their activation kinetics (Figure 2E) 
were identical to that of the WT channel expressed 
alone. Only the amplitude of these currents was 
reduced by a factor of 2 (Figure 2C), suggesting that 
the decrease in current level was solely reflecting the 
reduced amount of WT plasmid in these experiments. 
The finding that WT channels, when coexpressed with 
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the mutants, show WT-like currents underscores the 
notion that the mutants have no dominant-negative 
effect on functional channel.
DISCUSSION
HCN4 gene mutations were described initially in pa-
tients with sick sinus syndrome.6 In recent years, it 
has become evident that additional phenotypes can 
be caused by mutations in HCN4. LVNC is one of the 
phenotypes described in recent years. In particular, the 
pore mutation p.Gly482Arg has been described several 
times in association with LVNC.14,16 Here, we described 
another case with LVNC and 2 pore mutations in cis, 
close to the well-known HCN4-Gly482Arg mutation. 
We, therefore, hypothesize that this region represents 
a hot spot for the LVNC phenotype. We also observed 
a VF phenotype, not described before in HCN4 muta-
Figure 2. Functional expression of HCN4 WT (wild type) and mutant channels in HEK-293 cells.  
A, Representative current traces recorded by patch clamp in cells transiently transfected with WT or mutant HCN4 channels 
(I479V, A485E, and I479V/A485E) using 1 µg of plasmid DNA; control cell was transfected with GFP. B, Currents recorded from 
cells transfected with WT channels (0.5 µg) or with a 1:1 mixture of WT and I479V/A485E channels (0.5 µg each). C, Mean 
steady-state current/voltage relationship (I/V) from cells transfected with 1 µg WT (open black circles), I479V (grey circles), 
A485E (grey square), I479V/A485E (grey triangles); 0.5 µg WT (open red circles), 0.5 µg WT+0.5 µg I479V/A485E (red circles); 
GFP (black circles). D, Mean activation curves of WT and WT+I479V/A485E currents (symbols as in [C]). Lines show data fits to a 
Boltzmann function yielding half-activation potential (V1/2) and slope factor (k) values as follows V1/2=−103.1±0.2 mV, k=11±0.2 
mV; V1/2=−102.1±0.8 mV, k=10.7±0.7 mV; V1/2=−102.6±0.9 mV, k=12±0.8 mV for 1 µg WT, 0.5 µg WT, and 0.5 µg WT+0.5 µg 
I479V/A485E, respectively. E, Voltage dependency of activation time constant (τon) of WT and WT+I479V/A485E currents (sym-
bols as in [C]). Inset shows exemplary current traces (recorded at −145 mV) from the 2 conditions superimposed after normal-
ization. Number of cells: n=14 (1 µg WT); n=3 (GFP), n=5 (I479V); n=5 (A485E); n=14 (I479V/A485E); n=11 (0.5 µg WT); n=13 
(0.5 µg WT+0.5 µg I479V/A485E). Number of cells in (E) was 9 for both conditions. r.u. indicates relative units.
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tions; however, this severe arrhythmia may be multifac-
torial in our case and potentially triggered by the slow 
heart rate in the setting of previous treatment with ami-
odarone. Despite the fact that this drug was stopped, 
amiodarone is known to have long half-life. An addi-
tional phenotype detected was the previously reported 
mood and anxiety disorder.19
Our functional studies revealed that the double 
mutation and each single mutation alone by themselves 
were not able to generate a measurable HCN4 current. 
When they were coexpressed with the WT channel—a 
situation that mimics a heterozygous condition—they 
induced no appreciable changes to the functional 
properties of the WT channel. The observation that the 
double mutant does not act in a dominant-negative 
manner on the WT protein indicates that the hetero-
zygous patient presumably expressed only half the 
number of HCN4 channels, with only the WT allele 
contributing to the HCN4 current. This would result 
in a significant reduction in HCN4 current. This inter-
pretation is consistent with the experimental results, in 
which the current density reflects the amount of WT 
plasmid used for transfection. Such a reduced current 
density in a patient can lead to haploinsufficiency—a 
condition already described for another HCN4 muta-
tion, P257S—associated with early-onset atrial fibrilla-
tion.9 The P257S mutation is found in the N-terminus 
of the HCN4 protein and results in a trafficking-defec-
tive protein that does not reach the plasma membrane. 
In our case, the double mutation I479V/A485E is locat-
ed in the pore loop, between the S5 and S6 trans-
membrane helices that contain the highly conserved 
478CIGYG482 selectivity filter sequence. Further analysis, 
which is beyond the scope of this work, is needed to 
examine whether the mutations analyzed in this study 
alter protein trafficking or protein stability. Interest-
ingly, 2 other mutations in the selectivity filter of HCN4 
(Y481H and G482R) have been previously associated 
with14 LVNC.14,17 In these cases, the mutations also 
caused a loss of function that was either because of a 
negative shift of the activation curve14 or a lower num-
ber of channels in the membrane with a consequent 
reduction of HCN4 current density.17
CONCLUSIONS
HCN4 mutations confer diverse phenotypes, character-
ized by the previously described bradycardia, sick sinus 
syndrome, LVNC, mood and anxiety disorders, and sus-
ceptibility to VF as described here. Our study clearly sug-
gests that the HCN4-I479V/A485E mutant phenotype 
can be explained by a lower number of active channels 
rather than altered current properties. Collectively, the 
data suggest that the mutation reflects the situation of 
a partial knockout of the HCN4 channel.
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